Skip to content

    Alivus Life

    ALIVUS
    Healthcare·22 Jan 2026
    Management Summary

    Alivus Life Sciences delivered a strong Q3 FY26, reporting record revenue of ₹673 crores and an all-time high EBITDA margin of 36.4%, driven by robust performance in CDMO and API generics. The company revised down its FY26 CAPEX guidance to ₹450 crores and remains net debt-free. While the Solapur plant faces a slight delay, management is confident in continued high single-digit revenue growth and maintaining strong margins, supported by new product launches and operational efficiencies.

    Highlights

    5

    • Revenue reached an all-time high of ₹673 crores, demonstrating strong QoQ (14.4%) and YoY (4.8%) growth, driven by CDMO and API generics.

    • EBITDA margin expanded significantly to 36.4% (up 510 bps YoY), marking the highest ever reported quarterly margins, attributed to new product launches, favorable product mix, and enhanced operational efficiencies.

    • The CDMO segment showed exceptional recovery with revenue growth of 100% QoQ and 85.3% YoY, in line with expectations for a second-half turnaround.

    • The non-GPL business grew robustly at 16.1% for the 9-month period, reflecting diversified strength across geographies.

    • Alivus Life Sciences maintains a net debt-free status with healthy cash and cash equivalents of ₹733 crores as of December 31, 2025.

    Concerns

    3

    • Solapur plant operations are delayed by approximately three months, now expected to start by July 2026.

    • The company anticipates a 4%-4.5% margin erosion due to pricing pressures, though mitigated by new product launches and process efficiencies.

    • Geopolitical instability is noted as a potential risk, although diversified operations help manage its impact.

    Key financials

    Metrics

    18

    Periods

    4

    Q3 FY26

    8
    • Revenue
      ₹673 Cr
      YoY+4.8%QoQ+14.4%
    • Gross Profit
      ₹397 Cr
      YoY+11.2%QoQ+16.9%
    • Gross Margin
      58.9%
    • EBITDA
      ₹245 Cr
      YoY+22.1%QoQ+26.5%
    • EBITDA Margin
      36.4%

    9M FY26

    8
    • Revenue
      ₹1,863 Cr
      YoY+7.2%
    • Gross Profit
      ₹1,067 Cr
      YoY+13.6%
    • Gross Margin
      57.3%
    • EBITDA
      ₹620 Cr
      YoY+22%
    • EBITDA Margin
      33.3%

    % of Sales 9M FY26

    1
    • R&D Spend
      3.5%

    % of Sales Q3 FY26

    1
    • R&D Spend
      3.4%

    Segment breakdown

    CDMO
    100% Revenue Growth (Q3 FY26)
    Non-GPL Business
    16.1% Revenue Growth (9M FY26)
    List

    Capital allocation

    3
    high confidence
    CategoryHeadline
    Capex

    ₹105 crores this quarter · ₹450 crores (FY26) planned

    cut — deferral of ₹150 crores to FY27

    Debt

    Net ₹0 crores

    Liquidity

    Cash ₹733 crores

    As of December 31, 2025.

    Guidance & targets

    11
    CategoryTargetPriority
    Revenue Growth
    FY26 Revenue Growth
    high single-digit
    		High
    Revenue Growth
    Next Year Revenue Growth
    high single-digit
    		High
    Margin
    EBITDA Margin Range
    30%-32%
    		High
    Margin
    Margin Erosion
    4%-4.5%
    		High
    Capex
    FY26 CAPEX
    ₹450 crores
    		High
    CDMO
    New CDMO Projects Concluded
    1 or 2 projects
    		Medium
    Solapur Plant
    Solapur Operations Start
    July of this year
    		High
    Solapur Plant
    Regulated Products from Solapur
    late FY'28
    		Medium
    High Potency API
    High Potency Portfolio Meaningful Contribution
    late FY'28
    		Medium
    Capacity Utilization
    Capacity Utilization Post New Capacity
    85-90%
    		High
    Volume Growth
    Volume Growth (FY26)
    15%-17%
    		High

    What to watch in Q4 FY26

    5

    Solapur Plant Operations Start

    next quarter (Q1 FY27)
    CurrentDelayed by 3 months, expected July 2026
    TargetCommercial operations commenced

    Why it matters

    Timely commissioning of Solapur is crucial for future capacity and revenue growth, especially for ROW markets.

    Solapur is, delayed by like three months. So, we expect Solapur to start operations by July of this year. (Dr. Yasir Rawjee, page 6)

    Risks & concerns

    3
    RiskSeverity

    Geopolitical situation

    International business exposes the company to geopolitical risks, but diversification across geographies helps manage localized impacts. — Management acknowledged

    medium

    Input cost pressures from China

    Strengthening Renminbi against USD and weakening Rupee against USD could create a 'double hit' on input costs, but long-term contracts and diversified supply base mitigate this. — Management downplayed

    low

    CDMO business gestation cycles and deal sizes

    Analyst questioned the long gestation cycles and smaller deal sizes of Alivus' CDMO projects compared to competitors, but management emphasized its strong process development platform and regulatory approvals. — Analyst acknowledged

    low

    Q&A highlights

    6

    “So, see, there are three elements here. One is that CDMO has begun to contribute more. There's also launches that are happening across markets and usually newer products tend to get us much higher margins. In the first couple of years, we can expect to see pretty good margins, with newer launches and then it begins to settle down. So, we have had both of them, plus on the operational side as well, we have performed a lot better in terms of both raw material costs as well as the on the operational side. So, all this put together and this is sustainable.”

    Analyst questioned the sustainability of high margins, and management provided a detailed breakdown of the three key drivers (CDMO, new launches, operational efficiencies).

    asked by Pratik Kothari

    2 min read7 chapters

    Detailed Narrative

    01

    Q3 FY26 Performance Highlights

    Alivus Life Sciences reported its highest ever revenue of ₹673 crores in Q3 FY26, marking a 14.4% QoQ and 4.8% YoY growth. This strong performance was broad-based, with significant contributions from both the CDMO and API generics businesses. For the nine months ended December 31, 2025, revenues stood at ₹1,863 crores, growing 7.2% YoY, with the non-GPL business expanding by 16.1%.

    02

    Record Margin Expansion and Drivers

    The company achieved its highest ever quarterly EBITDA margin of 36.4% in Q3 FY26, an increase of 510 bps YoY. Gross margins also improved to 58.9% (up 330 bps YoY). This margin expansion was primarily driven by new product launches, a favorable product mix, and enhanced operational efficiencies, including better raw material costs and reduced overheads.

    03

    CDMO Business Recovery and Outlook

    The CDMO segment demonstrated an exceptional recovery in Q3 FY26, with revenue growth of 100% QoQ and 85.3% YoY, aligning with management's expectations for a second-half turnaround. This growth was fueled by robust traction in newer CDMO projects and continued contributions from regular projects. Management expects to conclude 1-2 new CDMO projects by Q1 FY27, further strengthening this segment.

    04

    Capacity Expansion and Solapur Plant Update

    Alivus' expansion initiatives at Solapur, Ankleshwar, and Dahej are progressing, with Ankleshwar and Dahej expected to be operational in Q2 FY27. The Solapur plant, however, is delayed by approximately three months and is now anticipated to start operations by July 2026. This facility will initially serve ROW markets, with regulated products expected by late FY28 following FDA inspection.

    05

    Product Pipeline and Portfolio Strategy

    The company maintains a robust pipeline with 595 DMF and CEP filings globally as of December 31, 2025. The high potent API portfolio includes 27 products in the active grid, targeting a $70 billion market, with 9 validated and 7 in advanced development stages. This portfolio is expected to become meaningful for the business starting late FY28.

    06

    Capital Allocation and Financial Health

    CAPEX for Q3 FY26 was ₹105 crores, bringing the 9-month total to ₹218 crores. The FY26 CAPEX guidance was revised down to ₹450 crores from an earlier ₹600 crores, with ₹150 crores deferred to FY27. Alivus remains a net debt-free company, generating ₹221 crores in free cash flow over nine months and holding ₹733 crores in cash and cash equivalents as of December 31, 2025.

    07

    Growth Outlook and Strategic Vision

    Alivus expects to sustain high single-digit revenue growth for FY26 and the next year, driven by strong expansion in the non-GPL segment and ramp-up of CDMO projects. Margins are guided to be in the 30%-32% range, an upward revision from the previous 28%-30% guidance. The company is focused on maintaining a high-quality business model, emphasizing operational efficiencies and strategic investments in R&D, including flow chemistry and green chemistry.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.